A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)
Sponsor: Multidisciplinary Association for Psychedelic Studies
A PHASE2 clinical study on Post Traumatic Stress Disorder, this trial is completed. The trial is conducted by Multidisciplinary Association for Psychedelic Studies and has accumulated 11 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Dec 2024 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Feb 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE2
Status: Suspended → Recruiting
-
Jul 2022 — Nov 2022 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Feb 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Feb 2022 [monthly]
Recruiting PHASE2
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Multidisciplinary Association for Psychedelic Studies
- Remedy
For direct contact, visit the study record on ClinicalTrials.gov .